Effect of fingolimod therapy on quantitative macular changes among patients with relapsing-remitting multiple sclerosis: a four-year follow-up study from Oman

PURPOSE: Fingolimod (FTY-720) is an immunomodulatory oral agent approved for the treatment of relapsing-remitting multiple sclerosis (RRMS); however, several clinical trials have shown that some recipients may develop macular oedema (ME) as an adverse reaction. As there are no studies assessing the...

Descripción completa

Detalles Bibliográficos
Autores principales: Al-Rashdi, Aseel A., Sabt, Buthaina I., Al-Mujaini, Abdullah S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9720917/
https://www.ncbi.nlm.nih.gov/pubmed/36471269
http://dx.doi.org/10.1186/s12886-022-02701-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9720917/
https://www.ncbi.nlm.nih.gov/pubmed/36471269
http://dx.doi.org/10.1186/s12886-022-02701-7

Ejemplares similares